Loading...
Market
Will Lantheus complete the acquisition of Life Molecular Imaging by the end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Lantheus Holdings Inc. or financial news reports
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Adding Neuraceq to Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings Inc. has agreed to acquire Life Molecular Imaging for an upfront payment of $350 million, with potential additional payments of up to $400 million based on future sales milestones. The acquisition aims to bolster Lantheus' position in the growing Alzheimer's disease radiodiagnostic market by adding Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease. The transaction is expected to enhance Lantheus' growth profile and establish a commercial Alzheimer's disease franchise. Life Healthcare Group Holdings, the current owner of Life Molecular Imaging, plans to return the net proceeds from the upfront payment to shareholders within 12 months of the deal's completion, expected in the second half of 2025.
View original story
Similar markets
Yes • 50%
No • 50%
Yes, both an imaging agent and software/service • 25%
Yes, a new imaging agent • 25%
No new product/service • 25%
Yes, a new software or service • 25%
Increase by more than 20% • 25%
Remain within ±10% • 25%
Decrease by more than 10% • 25%
Increase by 10% to 20% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
